Agree that rgs announcement is positive news for the sector. I was skeptical they would deliver on time but they have. And more positive developments are good for the regenerative space.
rgs has a positive Japan partnership & now phase I results. Both promoted as re-rate catalysts but rgs SP declined after the first and remains flat now.
Meanwhile msb value has moved a lot over the past year. I moved my regenerative medicine holdings from rgs to msb last year and that has turned out very positive.But I am surprised rgs SP stays flat as a tack.
msb has keen interest while rgs barely rates despite positive news. Is that msb's much larger mkt cap? Better mgmt and communications? msb further along with trials & closer to commercial viability? Or are rgs still wearing the ABC media drama?
But hopefully a rising tide of good regenerative medicine news lifts all boats.
things I've learnt over the last 14 months, page-25
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |